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Staging laparoscopy for cholangiocarcinoma
S. JOSEPH1, S. CONNOR2 & O. J. GARDEN3
1Beth Israel Deaconess Medical Center, Boston, Mass., USA, 2Department of Surgery, Christchurch Hospital, Christchurch,
New Zealand, and 3Royal Infirmary, Edinburgh, Scotland, UK
Abstract
The precise role of laparoscopic assessment of biliary tract malignancy is yet to be defined. The evidence for its use has been
reviewed to establish the role of laparoscopy for preoperative staging of cholangiocarcinoma. Published papers were
reviewed for the evidence relevant to intrahepatic, proximal intrahepatic and distal biliary carcinoma. There is no
randomized trial evaluating staging laparoscopy or laparoscopic ultrasound in the assessment of cholangiocarcinoma and
the quality of the available data is extremely variable. There is a need for further studies to determine the specific role of
laparoscopic staging of cholangiocarcinoma. The current standard of management should be to perform laparoscopic
staging prior to proceeding to resection for patients with cholangiocarcinoma as it may prevent unnecessary laparotomy in
up to 30% of patients. However, a selective approach identifying high-risk patients who will not benefit from surgical
palliation may be more cost effective and future studies should be performed to identify such patients.
Introduction
Cholangiocarcinoma is an uncommon malignancy
with an incidence of between 2 and 6 in 100,000 in
Europe [1]. The tumor may present as intrahepatic
(IHC), proximal extrahepatic (HC), or distal (DC),
and may be multifocal. Consequently, this variation in
tumor location may impact directly on its presenta-
tion, investigation, and subsequent management.
Although surgery offers the only potential cure for
patients with localized disease, it is associated with
significant potential morbidity and mortality. This,
combined with the fact that the majority of patients
will have limited life expectancy associated with
advanced disease (for which resectional surgery is
inappropriate), mandates accurate preoperative sta-
ging to prevent unnecessary morbidity.
While improved non-invasive imaging has resulted
in accurate staging for many HPB malignancies,
evaluation of cholangiocarcinoma remains a chal-
lenge.
Computed tomography (CT), magnetic resonance
imaging (MRI), and ultrasonongraphy (US) form the
mainstays of staging for cholangiocarcinoma. Unfor-
tunately, and despite the introduction of newer
imaging modalities such as positive emission tomo-
graphy (PET), they remain relatively poor at deter-
mining the presence of peritoneal disease and all have
limitations in terms of local staging. Staging laparo-
scopy (SL) is a quick, safe but invasive investigation
by which to determine the presence of peritoneal
disease and occult dissemination within the liver. The
addition of direct contact laparoscopic ultrasonongra-
phy (LUS) provides the ability to assess further the
local stage of the disease and to evaluate the liver for
metastases. Although SL with or without LUS is
widely used for many hepatobiliary and pancreatic
malignancies, the indications for cholangiocarcinoma
are less well defined. The aim of this article is to
review the evidence for the role of SL9LUS for
preoperative staging of cholangiocarcinoma (Table I).
Literature review
Intrahepatic (IHC)
Few studies have addressed the role of SL9LUS in
the preoperative assessment of IHC specifically.
Ohtsuka et al. [2] reviewed 62 patients with IHC,
14 (23%) of whom were shown to have extensive
peritoneal, liver, and lymph node metastasis at the
time of laparotomy. These data suggest that an
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equivalent number of unnecessary laparotomies could
have been avoided had laparoscopic staging been
employed. However, a small series from Goere et al.
[3] demonstrated a false-negative rate with this
approach. In their review of 11 patients with IHC, 4
had metastasis at laparoscopy. Of the remaining 7
patients who proceeded to laparotomy, only 4 under-
went resection. One patient was found to have
peritoneal metastasis at laparotomy, and 2 had
vascular involvement or distant LN spread. Poten-
tially, the yield could have been improved with the
addition of LUS.
Proximal extrahepatic (HC)
In the Beaujon study [3], 20 patients with potentially
resectable HC underwent laparoscopy. Five patients
had disseminated disease at laparoscopy, but of the 15
who proceeded to laparotomy only 5 ultimately
underwent resection. Again, the addition of LUS
may have further reduced the burden of unnecessary
laparotomy.
In a larger study from the Sloan Kettering Cancer
Center, Weber and colleagues [4] described the use of
SL in potentially resectable HC in 56 patients, 14
of whom were found to have metastatic disease at SL.
Of the remaining 42 patients who went on to
laparotomy, 19 had unresectable disease. Ten of these
19 patients were shown to have locally advanced
disease, while 4 had peritoneal or liver metastasis.
Interestingly, for patients with T1 disease, 2 of 23
(9%) patients were deemed to have unresectable
disease by SL alone, while 7 patients were found to
have unresectable tumors at laparotomy. For T2
disease, 11 of 29 (38%) patients had unresectable
tumors at SL and 22 tumors were unresectable at
laparotomy. For T3 tumors, one of four (25%)
patients were shown to have unresectable tumors at
SL, but all remaining patients proceeding to lapar-
otomy had unresectable disease [5]. The authors
concluded that SL should be used for all patients
with T2/T3 tumors, since this provided the greatest
yield with the least morbidity to the patient, although
it was unclear from this study whether stage had been
determined solely on radiological assessment before
laparoscopy or laparotomy. Of interest, the authors
also performed LUS in 23 patients in their study;
however, they did not find any patient with unresect-
able disease based on this investigation alone. It is
therefore uncertain whether more patients undergoing
LUS in this study population would have reduced the
number of unnecessary laparotomies in the unresect-
able group in all stages.
In 2005, our own group [6] published an 11-year
experience (19922003) using both SL and LUS in
patients with suspected HC. During that time period,
of the 235 patients referred for assessment, 122 were
felt to be irresectable following contemporary radio-
logical imaging. Eighty-four of the remaining 113
patients underwent laparoscopic assessment, 20 of
whom were deemed unresectable by SL alone (15
with peritoneal disease and 5 with microscopically
verified nodal disease outside the field of resection).
With the addition of LUS, a further 14 patients were
identified as having unresectable disease. One had an
intra-parenchymal liver metastasis not visualized on
SL and 13 due to locally advanced disease precluding
resection. Based on preoperative tumor stage using
the same staging system as the Memorial Sloan
Kettering group [5], 14 of 19 (74%) patients with
T1 disease, 25 of 40 (63%) patients with T2 disease,
and 5 of 16 (31%) patients with T3 disease were
thought to have resectable tumors following laparo-
scopic assessment. Ultimately, at laparotomy, only 8,
11, and 1 of the patients with T1, T2, or T3 disease,
respectively, underwent resection. The reason for
unresectability differed by MSKCC stage [5]. For
those with T1 or T2 disease, 22 of the 32 (69%)
patients had unresectable tumor due to metastatic
disease, while for T3 disease only 4 of 15 (27%)
patients had metastatic disease (p0.007). The yield
from SL and LUS for HC was 42% with an overall
accuracy of 53%. Although these figures appear
higher than those of Weber and colleagues, there are
a number of important issues that require considera-
tion. First, the Edinburgh study was performed over a
longer time period during which the quality of
imaging undoubtedly varied and, second, a selective
approach to laparoscopic assessment was employed by
the authors. These studies highlight that although SL
Table I. Summary of studies assessing the efficacy of laparoscopy (SL) and laparoscopic ultrasonography (LUS) in cholangiocarcinoma
based on location.
Reference No. of patients IHC/HC/DC SL LUS Efficacy
3 31 11-IHC
20-HC
5 n/a IHC- 36%
HC- 25%
4 56 56-HC 14 0 25% SL
6 84 84-HC 20 14 24% SL
41.5% SLLUS
7 23 23-DC 2 2 9% SL
12% SLLUS
IHCintrahepatic cholangiocarcinoma; HCproximal extrahepatic cholangiocarcinoma; DCdistal cholangiocarcinoma.
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and LUS have an apparent role to play in the staging
algorithm of HC, accurate assessment of locally
advanced disease remains challenging. It may be
possible to employ a selective approach based both
on the radiological staging and on the method of
palliation most likely to be employed in the event of
non-resectable disease.
Distal (DC)
Vollmer et al. [7] studied 23 patients with DC
employing both SL and LUS. Two patients were
found to have unresectable disease by SL alone (both
due to hepatic metastases). Of the 17 patients that
proceeded to LUS, 2 were deemed to have unresect-
able tumor due to arterial involvement. The remain-
ing 19 patients were thought to have technically
resectable tumors by combined SL and LUS assess-
ment. Of the 16 that proceeded subsequently to
laparotomy, 3 tumors were found to be unresectable,
2 had associated distant lymph node involvement, and
1 had related peritoneal and liver metastases not
identified at SL and LUS.
Technique
Laparoscopy
Using two 10-mm ports (one infra-umbilical and one
in the right mid-quadrant), pneumoperitoneum is
established. A 30-degree scope is placed and inspec-
tion of the peritoneum is performed paying particular
attention to the falciform ligament, liver (including
the undersurface) and diaphragm, porta, and lesser
omentum. By retracting the greater omentum super-
iorly, the small bowel and root of the mesentery can
be visualized. Any suspicious lesions are biopsied [8].
Laparoscopic ultrasound
This is best performed with a high-resolution flexible
tip linear array transducer. The probe should be
introduced through both ports to allow imaging in
two planes. Systematic scanning of the liver should
start with identification of standard landmarks and of
the liver parenchyma for signs of intrahepatic liver
metastasis. These can appear as hyper-, iso-, or hypo-
echoic lesions on imaging. Any suspicious lesions can
then be biopsied using ultrasound guidance. Subse-
quent to this, identification of structures in the portal
triad and relationship to the primary tumor (for HC
or DC) is important. The portal structures are viewed
by inserting the probe through the sub-umbilical port
and placing it on the hepatoduodenal ligament. This
will visualize the IVC posteriorly. By rotating the
probe counterclockwise, the portal vein, bile duct,
and hepatic artery are visualized. By withdrawing
the probe, the portal vein can be followed to the
spleno-portal confluence and continued down the
SMV. Vascular invasion is suggested if there is loss
of tissue planes between tumor and vessels. However,
too much pressure on the probe can artificially
emulate tumor involvement into vessels when it has
not occurred. A fixed stenosis of the vessel in more
then one plane is a sign of tumor involvement. If views
are not adequate due to probe contact or CO2
distortion, pneumoperitoneum can be reduced or
released completely and saline can be injected into
the peritoneum to improve probe contact. Further-
more, a 10-mm port placed in the left side of the
abdomen can allow better visualization of the intra-
pancreatic bile duct and pancreatic head. The primary
lesion should be assessed to determine its proximal
and distal extent (particularly important for HC),
radial extension (particularly arterial and venous
invasion) and lymph node metastases. Lymph nodes
invaded by tumor appear as hypo-echoic nodes that
are less well circumscribed. Although enlarged lymph
nodes may represent the presence of metastatic
disease it is not specific and should be confirmed
pathologically.
Grading of evidence
There is no randomized trial evaluating SL or LUS in
the staging of cholangiocarcinoma, and the available
data are extremely variable in terms of quality. This is
due to a number of factors, including the temporal
improvement in non-invasive imaging, tumor char-
acteristics, and the variable technical aspects asso-
ciated with laparoscopic evaluation. While the
multiple case series have shown a reduction in the
number of patients undergoing unnecessary laparot-
omy and ultimately decreased morbidity, the data are
poor at best. There is a need for further studies to
determine the specific role of laparoscopic staging of
cholangiocarcinoma.
Consensus statement
. The current standard of management should be
to perform SL and LUS prior to proceeding to
resection for patients with cholangiocarcinoma,
as this will prevent unnecessary laparotomy in up
to 30% of patients. However, a selective ap-
proach identifying high-risk patients who will not
benefit from surgical palliation may be a more
cost-effective approach and future studies should
be performed to identify such patients.
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